Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is March 16, 2025 Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2025, Vol. 30 ›› Issue (2): 193-199.doi: 10.12092/j.issn.1009-2501.2025.02.005

Previous Articles     Next Articles

Research progress on the resistance mechanism of anti-angiogenesis targeted drugs in the treatment of colorectal cancer 

JIANG Haitao, XU Yangxian    

  1. Department of General Surgery, Longhua Hospital Shanghai University of Traditional Chinese Medicine, Shanghai 200030, China
  • Received:2024-08-09 Revised:2024-10-08 Online:2025-02-26 Published:2025-02-05

Abstract:

Colorectal cancer (CRC) is one of the most common malignancies worldwide, although anti-angiogenic targeted agents such as bevacizumab have shown significant efficacy in the treatment of metastatic CRC, however, the emergence of drug resistance is still a key obstacle affecting the success rate of treatment and survival of patients. This article reviews the progress of anti-angiogenesis targeted drugs in the treatment of CRC, the mechanism of drug resistance and how to solve the problem of drug resistance. 

Key words: colorectal cancer, anti-angiogenesis, mechanism of drug resistance, targeted therapy

CLC Number: